Segall Bryant & Hamill LLC Sells 4,527 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Segall Bryant & Hamill LLC trimmed its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 15.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 25,497 shares of the company's stock after selling 4,527 shares during the quarter. Segall Bryant & Hamill LLC owned about 0.08% of Medpace worth $8,471,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in MEDP. Raymond James Trust N.A. increased its stake in Medpace by 34.6% during the 3rd quarter. Raymond James Trust N.A. now owns 754 shares of the company's stock valued at $252,000 after purchasing an additional 194 shares in the last quarter. Swedbank AB bought a new stake in shares of Medpace during the third quarter worth about $7,477,000. Centaurus Financial Inc. raised its holdings in shares of Medpace by 2.0% in the 3rd quarter. Centaurus Financial Inc. now owns 1,513 shares of the company's stock worth $505,000 after acquiring an additional 29 shares during the last quarter. Fisher Asset Management LLC lifted its position in Medpace by 6.9% in the 3rd quarter. Fisher Asset Management LLC now owns 124,399 shares of the company's stock valued at $41,524,000 after acquiring an additional 8,012 shares in the last quarter. Finally, Independent Advisor Alliance boosted its stake in Medpace by 16.7% during the 3rd quarter. Independent Advisor Alliance now owns 941 shares of the company's stock valued at $314,000 after purchasing an additional 135 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Medpace Stock Performance

NASDAQ:MEDP traded down $7.67 during trading on Monday, reaching $304.69. The company's stock had a trading volume of 602,622 shares, compared to its average volume of 299,947. Medpace Holdings, Inc. has a 12 month low of $289.01 and a 12 month high of $459.77. The firm has a market cap of $9.28 billion, a price-to-earnings ratio of 24.12, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. The firm has a 50 day moving average of $335.25 and a 200-day moving average of $338.90.

Remove Ads

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Leerink Partners began coverage on Medpace in a research note on Monday, March 24th. They issued a "market perform" rating and a $330.00 price objective for the company. Robert W. Baird increased their price target on Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research report on Monday, January 27th. Finally, Leerink Partnrs upgraded Medpace to a "hold" rating in a research note on Monday, March 24th. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $376.30.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.